Trials / Completed
CompletedNCT02640508
Eribulin and Lenvatinib in Advanced Solid Tumors
Phase II Trial of Eribulin and Lenvatinib in Advanced Solid Tumors (CTMS# 15-2139)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Virginia G. Kaklamani · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The overall purpose of this study is to determine the overall response rate, efficacy and safety of the combination of eribulin and Lenvatinib.
Detailed description
This is a phase II clinical trial of the combination of eribulin, and Lenvatinib. A cycle will be defined as 21 days. Eribulin will be given on days 1 and 8 of each cycle. Lenvatinib will be given daily during each cycle.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eribulin | Will be given by I.V. at 1.4 mg/m2 on day 1 and day 8. |
| DRUG | Lenvatinib | Will be taken orally at 20-24 mg daily in each 21 day cycle. |
Timeline
- Start date
- 2016-05-01
- Primary completion
- 2020-11-24
- Completion
- 2023-01-12
- First posted
- 2015-12-29
- Last updated
- 2024-05-09
- Results posted
- 2024-05-09
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02640508. Inclusion in this directory is not an endorsement.